Low-dose steroid dexamethasone to be used for treating COVID-19 in U.K.
Category: #health  By Nikita Chaurasia  Date: 2020-06-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Low-dose steroid dexamethasone to be used for treating COVID-19 in U.K.

As reported by credible sources, in a recent development the U.K. government has permitted the state-funded NHS (National Health Service) to use an anti-inflammatory steroid called “dexamethasone” for treating coronavirus. The drug is apparently a part of the world’s biggest trial testing for coronavirus and it is known to reduce the chances of death by a third among patients on ventilators, while lowers the mortality by a fifth for those on oxygen.

The results come from Randomized Evaluation of Covid-19 therapy (Recovery) trial, which was conducted by Oxford University. The trial primarily focused on whether prevailing medications that are being used for other conditions could sought as an option for treating coronavirus.

For those uninitiated, the drug is already being used to lower inflammation in various conditions such as asthma, arthritis and other skin others. Dexamethasone helps to reduce the damage that occurs when the immunity system of the body goes into overdrive, which can be fatal.

Sources close to the matter reported that around 2,100 patients received 6mg dose of dexamethasone daily during the 10 day trial and their results were compared with a random sample of 4,300 patients with no additional treatment.

The UK government claims to have around 200,000 courses of dexamethasone in its stockpile. Prime Minister Boris Johnson was reported saying that the recent development is a noteworthy British scientific achievement and has taken the necessary steps to ensure surplus of supply, especially in the event of a second peak.

The World Health Organization (WHO) has seemingly welcomed the positive results of dexamethasone. However, WHO Executive Director of Health Emergencies Program Michael Ryan stated that powerful anti-inflammatory steroids such as dexamethasone should be used under medical supervision since the drug can assist the division and replication of the virus in the body.

In another news, Russia has reportedly initiated its first human trials of COVID-19 vaccine which was developed by Moscow-based Gamaleya research institute and is planned to be tested soon on two groups of 38 people each.

Source Credits –

https://www.bbc.com/news/health-53061281

https://www.bbc.com/news/health-53077879

https://weather.com/en-IN/india/coronavirus/news/2020-06-18-who-dexamethasone-results-cautious-use-covid-19

https://www.timesnownews.com/health/article/russia-begins-human-trials-of-its-covid-19-vaccine-epidemiologist-says-mass-vaccination-may-begin-this-fall/608114

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...